
|Videos|February 20, 2020
A 64-Year-Old Male with Untreated Stage IV EGFR-Mutated NSCLC
A 64-Year-Old Male with Untreated Stage IV EGFR-Mutated NSCLC
Advertisement
Case: A 64-Year-Old Male with Untreated Stage IVEGFRMutated NSCLC
Initial presentation
- A 64-yearold man presented with shortness of breath, productive cough, chest pain, fatigue, anorexia and an 8-lb weight loss.
- PMH: HTN, medically controlled
- SH: non-smoker, social alcohol use
- PE: tired-appearing man, decreased breath sounds on auscultation
Clinical workup
- Imaging:
- Chest x-ray showed a left lower lobe mass
- Chest/abdomen/pelvic CT scan confirmed a node extension, a 4.7-cm left lower lobe mass with mediastinal and hilar lymphadenopathy; left-sided adrenal metastases noted
- PET scan showed activity in the left lower lobe mass and hilar nodal areas
- Brain MRI showed no evidence of metastases
- Staging: T3N3M1a - IVA adenocarcinoma; ECOG PS 1
- Bronchoscopy with transbronchial biopsy of the left lower lobe was minimal and insufficient, subsequent plasma testing showedEGFRexon 19 deletion mutation
Treatment
- Patient was started on osimertinib 80 mg PO qDay
- At 3-week follow-up the patient had been tolerating treatment well; continued on therapy
- Repeat Imaging at 3 months showed partial response
- Follow-up at 6 and 9 months showed stable disease
- At 18-months, CT scan revealed a new solitary liver lesion
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5







































